Form 8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, L1lTJP+KGaV0sn7fDvqsjdXYswH+nS+9GkWCKJKrHIafDR2C3tQqg4eqSnRKhPt/ BvT2jc3hMAkEUgSQCzlLiQ== 0001193125-07-259744.txt : 20071205 0001193125-07-259744.hdr.sgml : 20071205 20071205172736 ACCESSION NUMBER: 0001193125-07-259744 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20071205 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20071205 DATE AS OF CHANGE: 20071205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US Oncology Holdings, Inc. CENTRAL INDEX KEY: 0001333191 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 200873619 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-126922 FILM NUMBER: 071287467 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: (832) 601-8766 MAIL ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (date of earliest event reported) – December 5, 2007

US Oncology Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

DELAWARE

20-0873619

(State or other jurisdiction of

incorporation or organization)

Commission file number

(I.R.S. Employer

Identification No.)

16825 Northchase Drive, Suite 1300

Houston, Texas 77060

(Address of principal executive offices including zip code)

(832) 601-8766

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02.

Appointment of Principal Officer

Glen Laschober has been hired by US Oncology, Inc. as Executive Vice President and Chief Operating Officer, effective January 2, 2008. From 2005 to 2007, Mr. Laschober was employed as Executive Vice President and Chief Operating Officer of Omnicare, Inc., a national provider of pharmaceutical services to senior citizens. From 2001 to 2005, Mr. Laschober was employed as Chief Operating Officer of CVS Corporation’s Pharmacare Division, its pharmacy benefit management and specialty pharmacy business. Mr. Laschober is 57 years old.

In connection with his appointment, Mr. Laschober entered into a one-year employment agreement providing for an annual salary of $450,000 and annual bonus as determined by the compensation committee of the Board of Directors of the registrant. Mr. Laschober’s employment agreement provides that if he is terminated for cause, or if he terminates his employment without certain enumerated good reasons, he shall be paid any accrued or unpaid base salary through the date of termination and any earned but unpaid bonus. In addition, if he is terminated without cause, or if he terminates his employment for certain enumerated good reasons:

(1)

he will be paid any accrued and unpaid base salary through the date of termination and any earned but unpaid bonus, along with a prorated bonus for the period beginning immediately after the end of the last period for which he earned a bonus and ending with the date of his termination, basing such prorated bonus on the bonus earned by him for the full year prior to the year in which his termination occurs, and

(2)

he will be paid his base salary in effect for the year in which the termination occurred, plus the bonus earned by him for the full year prior to the year in which the termination occurred, for the longer of (i) twelve (12) months after the termination occurs or (ii) the remaining term of the employment agreement, with the bonus to be prorated for any period of less than one year, and

(3)

If Mr. Laschober has worked for US Oncology for five (5) or more years prior to his termination, then he and his eligible dependents at the time of the termination will also be eligible to participate in our group health plans at his expense in an amount not to exceed the applicable group rate payable by us or our employees.

In addition, upon the effectiveness of his employment, he will receive shares of restricted common stock of the registrant and units under the registrant’s long term incentive plan, the terms of which are to be determined.

A press release regarding Mr. Laschober’s appointment is attached as an exhibit to this Current Report on Form 8-K.

ITEM 9.01.

Financial Statements and Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:


Exhibit No.		Exhibit
99.1		Press Release dated December 5, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 5, 2007


US ONCOLOGY HOLDINGS, INC.

By:		/s/ Phillip H. Watts
Name:		Phillip H. Watts
Title:		Vice President - General Counsel

EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO


				Contact
				Kimberly Rutherford
				(832) 601-6193
				Kimberly.Rutherford@usoncology.com

US Oncology Appoints Glen Laschober EVP & Chief Operating Officer

(Houston, December 5, 2007) US Oncology, the nation’s leading oncology services company, today named Glen Laschober as the company’s new executive vice president and chief operating officer. The appointment becomes effective on January 2, 2008.

“Glen’s Fortune 500 operating experience, combined with his work in large diversified healthcare organizations, greatly strengthens our existing operating team,” said Bruce Broussard, president of US Oncology. “His proven success in working with physicians and healthcare professionals, in areas such as care management programs, process efficiency and leadership development, will accelerate the implementation of our company’s initiatives, such as Practice and Quality Efficiency (PQE) and Comprehensive Disease Management, including Cancer Care Pathways.”

“I am very pleased to join US Oncology. The company has many exciting opportunities to continue its strong growth as a leading oncology services provider,” said Laschober. “Just as importantly, their mission is very compelling to me. Cancer is a devastating disease that touches the lives of a large number of people. I welcome the opportunity to help improve the quality of life for cancer patients and their families.”

Laschober brings to US Oncology more than 30 years of healthcare operations experience. Most recently, he served as the chief operating officer for Omnicare, a Fortune 500 healthcare company with revenues of $6.5 billion. He has also been an executive operating officer in several other highly successful organizations such as CVS, Provantage, and Caremark. He began his healthcare career in a variety of engineering and technology operations positions working with medical devices and pharmaceutical products at G.D. Searle, Inc, currently a division of Pfizer. He graduated from the University of Illinois with a B.S. in Engineering, and from the University of Chicago with an M.B.A. in Finance.

He will be based at the company’s headquarters in Houston, Texas and will report to Broussard.

About US Oncology, Inc.

US Oncology, headquartered in Houston, Texas, supports one of the nation’s largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs and participate in many of the new cancer-related clinical research studies. US Oncology is affiliated with 1,164 physicians operating in 443 locations, including 91 radiation oncology facilities in 39 states.

###

GRAPHIC 3 g34925logo.jpg GRAPHIC begin 644 g34925logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`C@"%`P$1``(1`0,1`?_$`+(```$#!0$!```````` M```````("0H!`@,&!P4$`0$``00#`0``````````````"0(#!@Q\7(8&1H1``$#`@4"!`,&!`4#!`,```$1`@,`!"$Q$@4&00=1(A,( M87$R@9&A0B,4L<'1%?#A4F(S\7(6@M)#-"87&/_:``P#`0`"$0,1`#\`GT:4 MHTI1I2C2E&E*-*50?(?X#K@AK@6O^@Y_+K3S?D^OI\^E(5]P#MW6.H.`Y^VJ MR+8,D6AE)5[$,"JU^^4EKFHT`Z+]5F(&1&(K2:@/'9U1*F!"%)OS.4!V?V:[ M:[IW9Y;%Q^TC=_:[=XDNG_E$#2#GXN"-'QQZ5IGOIW4V_M/P^7DET]IW>2,Q M6C.IE<-*X=`I/X4RW[,O=JSAF&U8`RU8'MD)F68G+_5[).RO%5KD@R*TO889 M%FJ!4$RW(AU'B:*'$`>(FV`>8:]>>[KLOM]OQ6RYSQ6,N@VR*&VF:T`_ILC# M&.)&*,#0.N#NE>-?9YWPOY>87?!>3O:T[I++'2I18" M`G+X!^0>([#Y#MN&_EX#YA\PU'H!$X->U-6G#Q`.8_A4FSP[2H(+5Q^8_P`& MLFN:LT:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*H([!N.B@8N^G_"54UNLZ1]7 M^%KS9&3:Q4=(2DDZ;,F$:T=/GCUP9S+6U:9;V9[6,8`2I<0UJ@8E2>F-?-?7=KM\$MY=O$5A!&Y\CR0$#07$@ MHF`"Y&H.7N,]OGW<'/\`*6**=F+BNBF=U/%3$J8ID<0J#I,9.S.B&/S^ZM<@ MU]8"'\4VY4R_#4P?ML[9Q]M^$P"XCT[[?M]2Y>1CC_\`&W_8`T!"IS*U"3[D MN\+^Z/.IW0.)V7;R8[=@704SDD]L<`1&RQC!]]^$+:XM0T?/1#E8Z#50KMH]0,8Q3)D\%`VW#ZA@L M[B<6G[?\SO.,WS7@-F"Y[VM.N3$_P"%JI0`1V-MML/F&X;[ M>&X?$-?*UTK6$)CJ7IXU\4D;S&@^H."?(Y_C3POL_P#ON:5,.7F8%OBK- MSYHP:*.5A*PJ>2.!6D'+@HKR*@UL:!08.A^DA5004-XHQH"FWTG6[Q<6N#$#27*XH#BGM_V?]Y[CAG(CP?=)1_9K[_B+B4] M?4-(7)H(([;;AX;@&W\]16VXB9.YD2F08@ M(?XD(/EG4N+V23L;+"0TG-#_``\?F%%9-?;55&E*-*4:4HTI1I2C2E&E*-*4 M:4HTI2/^]'95#JKUPO65VOZ8O9VC8L+2&,N*I63ZYRW]F%05%`BBABI&`ZW$ M``#BD!1$`'6Q^T_`+CN7SRPXJQ19R2ATQ&;8VN"G^5:J[T=QH.U_;V_Y(?\` M[XB! MG+I MO+Y[F1TCW''S$E`?N%?!KZJ^6C2E4$3%$IR&4(HFX9/:R&*9C@0\$ M@M3%5&(J:?[6W=UEVPPBT@+4_9)YJQ8V;0%[8G6(DXL,6@BBWA+XT:@85#-I MAN0$G?F*+XA@'P.740'N)[1W':SFDQV^/_\`&+YSIHI`J,<2KHE/5N?R*#(U M-/[:N\MIW1X5!#>2IRNQ8V%\9S>T``2^!4X?C3I']?QUY]KTS1I2C2E&E*-* M4:4HTI1I2C2E&E*Q&./U<3`!@\"[&`!Y?+Q$`W^0:I)TDM/T.P!_W>`JF8Z0 MP`^=5/\`V^-0_P#WDNVO_FC.1,/4J>^^QUB$IHZ3/%S"CB*L-\47(E$1\1#Q$FQ1Y!KV&DI<3`4N""T'YA$^17&O%"1ANEW_%F4^'7YCI M51W'X;;!XB&P!MN!?_40U1;,G#S'F!+$7&%W^JC;;_`-P'X_,/ M`=5ZR\ZBW0H91H4%FYC`/INTB&\@UK;NWV[VONAPF]XG<%HOB=<3W!2QZ%'-.8Q14S&% M;0[/]S]T[7C+'7Y%$X<'49*-4G+8YR!N)%P`PD4((B)%"&*.PZA/W_:K[CF\W.VW['- MW*T>8Y(BJ!"?,`?AB"F(2IX>.[]M_)]GM-_VIPDVB]C;(QX^(^G[\*W0H;`( M;F'Q\S"(CY!Y;Z^%C"Q@5Q0K:8U>1DT)`Z,N\B94L@^?-2!%J)JB#,$A*IL58AP#6^/; MYVL__:W+X[*YE%MMELX2R$QN?K+7#R@@L`Q.9)^1Q3S[[D>[L?:OADDMM#^X MWJZC,<:2!A8UP/F32XNZ8!/G4*EPX7>.'#QTH*SIXX7=NE3^D9PWKL&W`ZD]9)`I3%$K*#9)G,?EQ`ZHD(`[FWU M@_/N=;;V[X=?0]U>.S?W(-9R6UF?ZK`Y0Z-SRZ-[%QTAC MFM*]09IF3>I^WE:6.`4_TZ9UB, M)N0$(4QSF$I0*4IQ$3&'Z0*`%'U!'Y%W'\-41,MF3_N',5Y^/^5?9ZKQ!Z#< M&=*E'^RKV)G&56#K5?%6WZ0ZC)F^8'EEIEI(K/(AG+`GD*B+JMQXDF*Q(O49 M%%EQ(LG'OBCPV#?47_NVX9:QV0"1GT%S$HSAHQ-< MR2A&H.9&0$&C<#+B4`$VX[^0#KZ=HVV[WS<;6TABE=+),A:UCG.12OE&-=9O M^^VG'MGO-TNWLCM88-0>]P:WI^8D#K4#'MEGK)/8K-%GON3)E:3=LGLE6JT@ MV5,K`QU>A91TP1;UX5$6_JQ+MRFLY%38XBHJ;ZMO`)J.TG">+<.X9;[=LD+8 M=XEA8^8G!_J%JN#QF'`E"#B,J@Q[P=P>3\UYK=;GNTKYMF9.]L`Q+/2#O*6Y M@A$0Y&DTAK:Q8`X-#3ZI"'X_+QK3X+G!5!:2H'450Q@*!A$Q`XD,<1./T@4O M@8Y@W`>!1'QU:D>&AXU!KV-)/^T`*2?`#,DUR`Y1I:7.)0`9N/0#Q)R%2_O9 MVZ?M\'X,99DN$(DGE?-3)&7492,,@ZV$IC@LD4 MP?1J)GW/]VKKGG,_['MKUX]MI]-P:5;)*`=3\,"6DH/M/@DQOM%[/6?;_@S> M5;DQKN1[IYV!P\\3#DU,PJ+\J5[WZZFQG;_K_8\>$28MKU#B%GQA.NBB7](N M,>F<&R"K@`,H6*GFICLW12[!Q4*&#U;9PS;(T*YO_`*E*"H+MBKLY4;#. M52S1KR&LE9E9""GX=\D"3N+F(MVLTD&3@H>/-NNB(`80#F00,'@.IJMGW+:] M^V>WWS:'-?8W+`^,M((TO`PE*V9HLO1:3F.:<`PFHFP??,W"#-U:*+'NT"/D2 M'%5=)("_4`"'EOW#6VTW6TLW3?@S^QZ]%Y'"X>O+!^32`I.EY) MWB]W>SW!]GQE70Y20N"L<#DY!Y2F1:1F*ENX#RRVYKQJ+=H4%XQ8[E@SBF:4<'#\N MK!X!S:]IR-=SW#?;<-_+;<-]P^&L?((SPK,]+AT-5UQ7%&E*-*4:4HTI6%<> M*)Q^0`(;`(CON&VP``B([_#7#I6PCU'!0H'WE/YUI&,JE-&=%9-%$##Z M!&KA0!`YBAKWY[7>R-Q+N4?+N11EL8A;-!JP)U@X)_VH<<]03*HX/=CW^VF\ ML'\*XI+ZD[I'6\P;](+"A"Y8%OCTJ/6[E9^?29$>OI*4;U^,^TC4U@.Y0A83 MUU'"B+;B4?LX\SMV80W#AZB@CRW`->_;>TVZQD=>QM#99CK=\2?'X]*CBN;C M<;Q;6?'T_+AEAA7DE^>WA\?X^.NT9JO4PKE-0?B'HHNII^D!ED1'^ZU`0VW,77 MFWW,]S(>W?#CMNU2!W)]Q:^((<6M>W27'J``N/B17J#VQ=I9NYG,XYMRC+-B ML7LE<\C![HW:@P$X'4@'VFINK9LDS;H-6R*2+=!!))JF@D"2***1`3(DDF0` M332*F4`*4/R@&P>&H@A'=N]:XN)"^ZE>I)^S[S\:FBMFVMF8;"WC#+:)B-P0 M##(?TKZ@'^(CYCL'C_77+8"'^J'(K0"/B@JMSFPS$.8KE4'X'_K41_WKL!*U MC/A\Y5^&48P%XCH-G:7;9F^38R%F(FHT2E"KG:I1Z[LS5`A7@IJ"<3<#"41` MXZDV]G_.W7O$W<0O)=5W9:BQI.(C+BN&:`D)X95%-[SNVHMN8#F-E&EG>_6X M#.1%'VGS4R1L.P&\0Y>(#X;#MX;@/Q#D`A_+7M>"+]SCG7@U/UO2Z5[<+99N MJ.';V$<_:/56+MHDY(LZ*LS6<)>FVDF"C9=NJA+QPF$6JY1YH'.)BZZ??=EM M.26LMO>MMPYK3I"!2G0KF#U'6L@V'>9MFEBO]MEG9/Z@#@"F`..7P)J61T/R MI1:/7X:7HARQF&9>HU"8RQ*1LS*6FG5?+TC!P<=++.I![!!*IV*RS4DA]^LJ M\.D@+=558&&*#O#QS>+O=9(-[:#ND$LC;5J,C0^&^O-CB_U':LAAIZ@BO7C2V6-KH7ZH4U-<,0YIR3[Q]U M9=<5S1I2C2E&E*L,80,4OP-OX^'@(`(AX?CJTYX:YQQ!1?Q_G3=ON6]J;1U:P#^N4ED(VN[SJU*C)M5,3-*J1S#O7*\R MN?TUD@>`8B:;,HE$#K*!_P`([;I[#=O['N'SANV;JXNLK9K9S'B/61S$CU-Q M`!1Y$J+BNE!FA=EX0G7)C!J7^RVNVV MFUG=;$0NMH&M@C'^EH`3'ZLNJU"A-?WFXW)NKYQ>^>4R2/0*)7%7')0JNPR^ M&5=.R6KAN-CXR'Q>]L<[9@^["\7!%%Y4J)()"5FW:P=4J3U:1EUV311H8[A\ M\=`5XK_<202*/$,9X/!S?>-QDON4B$;,\+%'@'M"G%SF:5+@B-3RX@DFLDY+ M/Q';MM;;[&9/[FTH]^+@XC,C4O7K7+*U7)BX6&$JE=0*[G;'*LX2*;**`DFM M)/W";=LFJIQ.*12F$1,/$=B%,.WAK.-VW*RV;9KN^N98V6MK$Y[@O^D$M:"> MKD(SQK$=EV7<.1;W;V$#7Z[F5K`4Q`<0'%!T`()\,*FQ]/NI#7!5-J-1B8J/ MK-8A$(62L#B/!F_L>9+2S*9`NL_ M'^65;S>?4^O%*IP+]7@/U?F\1\?Z^&N"T.4'J0OV547N*+T"9"DC]T^K=5[6 MX2EQRPMG: M#M`QC'27273,78?,``WQ#4UO&>06N^[);;SM"/M+F,$.!4!0"OXU`_R'9;GC MV^W6SW49&Y6\KFD%0J$C+[*U\1$0V\/`0$!V`!W#Q#Q\_`==@]C7R^LX?J>/ M^,*Z1L+&G4`0?F?ZTL_IIV-=85E\G8\D6AIRE=A:%.8QD("0FDHFJ,;A9$31 ME4N=B!R1=NDPA'STQG"Y$O5(0W/<2E$!T'WN[7P\[BL=UL2V'>=HF%T7!I)D M@C5TD(`P+I`"T*#B?%"/1/8SNK)P9VX<>W0&78=X@_;H2FB9Y#6RZOJ'I^5V M!3#*I:71C/2>1Z>EBB:1D6E[Q!1<9)OUIB6;3CZZU:?J+$\+?T99N@W1=I2, MBQ>-7)`*)TG+<>0CSWU&+W)XE<;+NLG(V!K=MW6XG<&`$>A(R1S?1(Z>4:AX MC&I6^SW--MWW:W<4;K_N&SQ0,:\N)]>)T329`2J@.<&GXX4O3\/CY[?X_AK6 M-;HHTI1I2C2K1E`D$:%37ERDLQAV3V1D7!6;%@U6=O72H#P;M6Y#K+KF,4#* M`":1!'Z0$1^`:NQ1RR2LBMX_4GD>&A$ZD!,2/Z51>W,%C&^2[D:V%D9>57HJ M'`>(J%[[CO9&:['WA[*AD@L]6ZG/VJN,<RN?%9Q>I=0-D;.\M,S)B&Z@0%+(D! M#=+BI(\H*FH?_M`GV?Z>8486!EVP22Q&TP,>DY1=R9RD0.FN4W$BG,IMR MZW_)MVX3[E;;C?.9KA8X.#7$@DD88M&"-_DG6O-]GN.TV6W36EG&]\TMP7K( M``&>9!@25\P^ZM+>Q#F/9MWJ@)'8O`*1F[26*9-90S-!W]N```*D5(D[3`X& M('$3:R.WOK9UN(@&BY=(A4D-!\`@R^RL;W.RNHG07#_^"5N&E"5"*JIX^-2& M?93Z31\\0_;F_$BGK1C(S-?Q?7E&K)\#ET=H,?8[#8TG2#A1M]FX$J46D7TU M0'U53>!R:C[]W7>`VUT[MSLT;[68>>YE!+6R(?TVQD>8@$.+R0,'``'%)%?9 MEV7M]R@9W-WZ:.XMHI'1V\&+G-<@]1TC2-*(6:$+BH.=24B)A M*)]!2-HP`!'7XYIGTK*98A0`P@IL)@*`^F8`$1^("(;"7\=5&:,-#E\IRS_I M538RXD*T(.KATK`#]H8IU"N$3IIF,4RB:R1R`8G+U0$Q3B`>B)1`^_Y=AW_* M.UXMN73K5CU(S]+FD?`C^M4,Z1612614(LDZ MZAPE948=M*HL+9:U6>&J>2H$"Q;*);N5V"C>$LL>T1;)R#N3EGS?TWJIE#&' MB4PAXCJ0?V==W+N>Z/;C<3)_;4U0R.!(`5'`DA0T*W2G3IA4:WO9[2[%;Q,[ ME[,!%?2RF.5C2T$NS#D:Y"OF514>01#5<.D4-<7.$>L(F>K M!3FF`R^-2,_:7SU6EZVM)#055+]@Z@KX_MEM1GHFO1-CQS:;PE/U%*5;_8", ME-5MR#LC-5R<"@!SD,H!E`VC<]TG;W=-MW>-D,K7;7N5PVYAB!0`98I+ACHR$*ND:2P'5D MT.0E`LEY%0%"%$HF.7B`E'B`%$HB/$Y=@*``0[^`:\-ACR%<-)4X%% MP^2U()ZC')Z9U`@'!>OS2LH#N`#XAN&^P^>K;'![`\9$+5QPTN+3TJNJJXJT MQ@+MO\1`/(1'Q^`<2F'O>%YZO4"RD893L4A'5>T[>Y?-8Q=0 MMDL+4%[]2@'2`X!4(3/#KB*\P>Y?O-;]O>$R65I,Z+?[DHS2`?(2&XX@C$'I M40N[9+O=]3)_NFW.Y]!_8IRZOXY5595%I;K"BQ:3\D91V4ZQY&53BT#K_4(; MAX;>.\K?&N(;5LCGW=C:Q0AD;86EKL0(\&M32,`KD'1340._R`'202?'XY5;N9O5`CDG01DD#P^%*1POW&[-=<(A[`83RQ/46NRL MI^M/X%FUA7\2XE/MDFIG8-I:,?`@JH@B0I_3$@'X@([B&M>\[[+]O>X.Z#>. M4;+;E)!;.D+W`*X$E`,%"9 M&NNS/NB]\YYE^GO>PEE;HB11,RL3&UV(=""JZ"XG%Q'13V3LO8DSQ;5*7-1WG)>/+CB'+AXIG6;R>ZWO7=L_;'>9D>-.#=)\V& M8]I(I%LFPSUDYL#5%RFT-_N5XH=J60(T*^.@#GU?15>D9)@H80YB4! M`1^H_+[;OM!VOEF+[W9[?]PYK048U"`!I_+T%6[7OEW1M8?0MMYN!"USD5[B M5))/YJW5MW[[FH2WZVCV)R,$D2-=Q+=0))J#9HP>)"DLFUC2,RQB"A=Q.10$ M?434^HI@'71WO8[M!+"V-NRVZ"5KRK1B1XE%/10201@<*^Z'W"]W;1QECWN< M.TD?6[(Y@8YTFJPWB[VL@IVNZ6NSHBX5=_;SUEEYA$KM5118[DK>0=.$2+`J ML8P"!0XF,(AMOK8.R<4XEQ][;C:-LM+5S4\S6-!_!HK7>Y<$7^$R)0)#[25AW34[^*77<)PEGB$'*"[VNV)!NJD=[#2:2'IK%$1.4 M@B)!`=]\#YUPG9N?;)+M6[,':L7"B8*N&A$SJ;GY",*W-MGLMEWLV>VQW$4$3W`^J$)0D$ ME,,7Q7-P2&*2[(:$'@&ITSI0V`NK@VY!Q8 M,TW>A8(QI*QQT/\`=&3YQE&2OI`W+-L)6HU/[HT_84'SI$C8Y4$DA.BY,8JN MP;:UEW$[L2;'.^RXM97&Y[\`D44#2Z(O.`UN`+1IQ=FI+4K8?;GM:-TC9-R^ M]LMKV-[E=-*X"6.,8G0TEI5P&CY.6O8[F6GKG&2%7PYU)>1\UA^"AH6P6J[I MQDFWL60LEBF_9/7LK+SS'V M54-4&KL&9J[7%7G?2?E5NN:^*JA_C_`Z&OJB^@5:"A1-P`?';EX?\.^P&^?$ MP^7SVUQ5U,%Z5?I2K=0>(C\@_@(^?X:H>[0PNTZD MZ>-5,)#@6G2?'PI?/MK9R98+[88QL5@LDI`TZ1>JUB89HS3J.@I$;."40W// MIE(LR6BXM5D_;)S@\'[JVEQ>W9%C/^DY7$-\Q&85.E3F6BZ#EJWW`CP(S'V5-]$^.2)LD+M4+@"T^ M(.1KZ-<58+^VAX]8-U^B6.+Y'9JYP>A(3#`)44",D%XU MZSDV!_2=1[IL\9K*`DL4'#50BZ2QDEB*(+)&.0!X&`R1B_#8=M2I2PQW>N*9 MC);9&PB`;`)A_,;;;B!C#Y[: M^@W$W_*DGK$?4G^5?#/(;@M:?3;&TX-:?ZDE:Q%YF$O!(ZH']0$P1+ZJB@D' MB82)IB(\2&\Q$0U\UU>VUG;"ZNU#"[2J@>;[JO6]E/?W1@@QE340`3A6T56E M7&[N7+&GU2Q6M^T^V^Z9UR'?RZS,'2@MT#NR,47!D`6=%%,@#L(F'Y`(AUN\ M\AV3C\39]XN8H('9%Q']1EF:[78^.[QOD[H-HM;BYD;@1&QSBI^G(%%_Z5L< MYAG,%;@S66+GO#)[IME;[K:2W3P2UK2.@4_F.77PKO9N`\R@MC=7.T[A%;QG3( M712`!QP`"L"*HSK5'-6L[3USN:U86R#91XBNHM"RA/268-F3QZ@8RC--,%63 M:2;*+^.R::Z9A\#AKM(>1[-(=+KRU!\/4:N.7YNJ'[CX5CO_`(QOP@=+^SN5 M#D'Z;DS3'`_RJU2LV-!2<16@)M):L@4;*5:(?(DKI5%&Z"9YTRB(DBN2SDA0 M!TZDS1'8Y'*JQQ[?VM>66<_IQAI<2QP M(U(?`>.=>U'UN4_02R-@(]A:BTFVS1R]&)14D@E'*,>FX;MD7*S%X[.1BY(L MFF)O3$I@$O@/+H M\4TCXXJE7UR`F+=,M:Q4X.9M-FEU2MXB(@&BLF_67]8/4_[)BDY64(1`I@,( M\`(8-Q'8-7-RO[/9X/[AN=S;0;2,Y7/:@^S4#5>T[#/N[C:6L%S)N?2-K2/Q M+37E*(*HEW70<(@`G*85D%D`YHJ&17#^\F0#"BNF8AN(F`IBB&^X#J_97UCN M+?6V]W[FS3&1A&EI\",4*8XG(BNMW#:;S;)C;;@UT%XN$;P=1'B,L%PRZ5WS M'?6;.V1H:5ME$Q-:KK&UOTWD@TC(E21579!^F%550CVSA.1DRHJS;3D1L0YP M*H)A`"D,.L`W_NGP;8=XBV3==PAMGS.+2XN'E.DNQ.0720"4!Z8UL7CO9_GF M_;2_?-JVZ>ZBB`.EK2=2N#?<-VOV/;[JR@W5EU))$Z M-H)U#)3]*)@,"2BX#$UL#C7M[[IW^YPSW.RW%O`V=CM2%K@%/4@J,?!:G'8V MAUZ_CRCP+HZ2CF#JL!$+'04>K(F/'Q35L84EI)1606(`I[`=+J\M`EK+.]S,OI),P\5/1KN(G(UA*Q;Y$S62C)-B@_8/6CCD11)VS=)JMW+=7AY&*8 M-P\M]M1P%!Q+UT`"J2HRU@J[(XEYF%QSL@F=:.W?VQ]C]]N1>7N MR,;,B(V25HS)R;(!F36G#[.G0D3LC%QA.(_9-WCD8.?QKK![3NQ,1UP[ M/IDZ'UI21T_,\C*M//[)?10Q!1+6LDDV261!0':M1<279XAN``P1 M`E9!MWMG[8;5N+]TM+0>H]ND-Z-'@.GVUO>,.B?77$MFB+?3J+&,;!7WKIW$ MR**8MG15GII!54TDX:F(,Z<7$JY51%X53TP6XE`"%(`=)R'NGS/DENZUW*[= M);O`!:2>GAX+U1/'.LGXOV7X5Q6Y_<[5;F"747:FAI4CZ5#@50Y?C71F?6ND M_9V".FC.K#%VV7B9RU1;YI!-64])UU5H>NN':<1&L!0_0RQK8B141("GI!ZG M,1-OC4?*MYBN6WEL\QW#(GQ@ZB7!LC2UZ$DH2"0O3[*RE_!MIN(3;7SY)H9) MV2O!;&&ZHW-BE/F?&K_P#X M1QST)8?VEIYW$C](=4^'PKP9_J[BBU5O(U9GJG`.H_)Z482R^G!0K=RY MUCHR0=NTF15YIXS09I&(H^%?=1,NY>(:^VWYAR.UNX+BWNY@VWU:`7DZ=?U( M%(:JGZ4KY[GMWPZZ@EAELH-;;.9[&_FCE+VR+J)'J`)D5S0:E!!.)QJQN79;MUNT`M[ MS:X3'I]/``'1XJ#_`)UM3/IKUYC:]8JQ7Z!$UQK9HZ1B924JB:%8L:43+*-3 MRL1'V:`0C9I@PECM2^L"*P&,7F`&#EKJ[SN#S.YN!=R7\TTS2"&RN+XM05'& M,J"02H)ZIU%=Q%VMX/!;?L8=O@9:Y:F-TRIAAK\*T&^^W+U*R?8*=8[SBU.< M6HE69TZLPRT]-HUEC`,3.#MVBL,S?M472I%'2AC+'$RISB!C")M]=_M?>SNC ML&WS[3L^XF*TNY3+*C6XR$!I()!<`0!@,!TK&]Z]OO:GD&YV^\;GMX?>6L0C MC5QQ8'.>-0!0D%QQ.*84K.F8]IN/HR+A:=7(V!CX:(:04>5BV2141C&+=NBW M077((*O#`1LF43J%9$"UQ8'D:0S'`9X?#YUD#R\MOB/EY_'R\//5PAH*-^FOGCU: M!K^M,:KKBJZAX7KW$>^=7_<:4;VK(_M!9%.L4\RK[Q^XHPKM`J<@S M&)BHB$C6#9VY067=**$*1,RE*ZP=DWM1`=ZLH]4\PO:W=,+UGK;53S56L/=G\79==P5 MHL["JW>)E%XW*6*;?&0$#*PEPK[Z$4(M$J'<1$B1/+U4\HT M&DY+HM'#5*3COM/ MU"-571,B1^P"0:/F17C;ER)ZJ*J0F#ZB&#PTI473]OW[C?<3NYVH]S?%G9O* MR.1JEU=R%%4;$K9.E4FIN(V-2R/EBM+O95>H0$(,Q*/(JJ,RJ*K`(`)#"4`Y M:4J4UL.V^P[>6_P_STI5!\A';?8-Q_@'B/\`#PTI2V_P#[6\5B/E^BT[^O4"8`-_EXZ4J95W<' M?JOF;C^8*U'B&X<0`P66!,4=QV`!`WC_`!TI4+GW7_:-]UO!W?G/7N-^T%?; MY9X+.]IDI_(L'@2^LH?*-/NP&2;7VJS=+" MN!@*4>!@D)X.7(?%/Z!$NX>/CMY".E*C_P"->]W?CJ[BK]N+A7!782YUZK]I MJ=!QMXQ]:BUZ2J,E'-NS)\<4IC]T:`-9HVGEI+IOZS-L\(9R@4"E_4!AV;R=F?KQVZQY!O,H8^S`K6)&'KT_/261(UU9L=#"5Z% M5I24>ZJ+9T@S1.=N5/U$3@H4P&!2M@Z9>Y)V*]VRS>[!E'#DED*(QUU!K#RF M=+,!8KM:6.I_)F0#P.1GD/=\AW)!-P_F)ZY3549$CH]14L2P1<"F=!17=45* M3A->\5[CE8QW[2G13L17Y;KSWT[KY4CJWV&R')5:'BL@TWK\TS&;';&5::1;3)$S_N6Y89S;(WRT4:$GZ[",]N-3]QWV[D()"T2F-,N0$=2ZJ[<':-+%D6Y9^SA5:3%R#A M,/52B2SLDFN]$G]S[1%0"?6)0%2GB\F]SNZ.(?8EP[[P;'L%N2Z"+)ZR5)-)ND!7%VIS,32E=MQ MK[H.1O<&]QKV_P#`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`U'(%AQ:Z@)VA(Y5H$'ZZ9[=/TZJ6 M95*0B6X"_=LV3<[8%#D,GI2OO]Z?$E[]W_$>!^AW5V%MIZM<\[4_*783/=EH MMPIN/\*XIHD7+^H@Y=W2'KR]BR;8I6>2)&P#!)RY_P"V4,Z^W(7F*E-P>[7T M(RW&>X9[*$;U.ZPYPNW6WV_VV(ZK?[52<962Y!@#L%E3]P][=7;>B==,\W'K9@RG46$RYE"& MQ)=7E=K#@TWDV2>-E#)QA7C\[>-MK,5A;I*`@HJ)#['34*52NA>RYU-R![,O M:;W!L)YLH639'">?K73\I]8<[4K'5QOM0NE7AW=U!:C6(:;"STC3LFP<996A M58V31;_=*)JB@8Y>(F4KY_=,Z$=ENP_=WHA[M5!Q7=)J`ZL9KQ=7[MU_9Q#5 M3-:O76HY`+;%LD,>4;1/VQ@3%<5D$U*WCMMTRM/N/ M>]?T[[AQ57O.+\T92RM70F)T&3AO76,VVDV#9<'?IG*G(\B%4,F8FE*<.RK@K MLMF/]O9A/VG*KU[RQ&=UB'Q-@:WT2TTF;B*C26F.,M)3UBRC.91.S5QX&,C5 MJ#(\:2;>2<"\^Z3213,L(D!2DC=K\_W#V7*ZK.3$@I?LD"]2.C(.4TD(]!%,C83"*QE*>A M_;W>Y?UZ[=T;+O6;$73)[T/M7752(N\YAU63D)YE8(S)4E)*+WMQ/3L#7K;* M6A[--!_4595)9TY%9$_KJ%'8JE<.Z)>U6_ZS_N&N]N:*[]W%]=I+%4!GZAUI M@H!*X?)N?Y>=BY!F[C4S^G]Y27\5;5&`G(!FS65)P\#F$5*E9Z4JPGI_3Z>V M_P!7#A^;_FX\?'R^7PV^&VE*JIM]7J[_`)#;\^6_#_5Q^.W_`,?P_#2E7!MR M^G;GM_HVY\>1>7Y?JVY;V^E*N\?^;\//;R/OM\ M/+??;2E6A_HVY?E4X[\N.WAZG+?Z=_GOX^?XZ4H3VW'TM_/ZN&^V^X_GX_3R MW\M_'2E8P]'QX\-]R[[;'';ZN?+\NWC\M*5>IQY_P!W\^P;<]]MMR[< M>7T[1M]]]M]SX1'QL5/Y>ZM,]9>OUYK$?X.=94R3-2$V$7#G MFY%&&81[$')S@N4^E*7S[:'_`)W=UK(L]W*"NQ7>:Q,\1/.Q-%K)VSJ&Q_&Q G^.6L)CZ)83,2BK49HMA&,E9MT>#=O8YI)2:[0JPG0,`*4Y[I2O_9 ` end -----END PRIVACY-ENHANCED MESSAGE-----